+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Myeloid Leukemia (AML) - Epidemiology Forecast to 2030

  • ID: 5357285
  • Drug Pipelines
  • July 2021
  • Region: Global
  • 220 pages
  • DelveInsight
This ‘Acute Myeloid Leukemia (AML) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of Acute Myeloid Leukemia (AML), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Myeloid Leukemia (AML) Disease Understanding

Acute myeloid leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

AML is the most common acute leukemia in adults and primarily affects older people with a median age of diagnosis ~67 years. Each patient generally has a unique profile of cytogenetic abnormalities. Older age is associated with a higher frequency of abnormalities.

Acute Myeloid Leukemia (AML) Epidemiology

The Acute Myeloid Leukemia (AML) epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total incident cases of Acute Myeloid Leukemia (AML) patients are increasing in 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Acute Myeloid Leukemia (AML) symptoms epidemiology segmented as the Incidence of AML, Gender-specific cases of AML, Age-specific Cases of AML, and Genetic Mutations in AML. The report includes the incident scenario of Acute Myeloid Leukemia (AML) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Acute Myeloid Leukemia (AML) Epidemiology

The epidemiology segment also provides the Acute Myeloid Leukemia (AML) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The incident cases of Acute Myeloid Leukemia (AML) associated in 7MM countries were 41,715 in 2020.
  • As per the estimates, the United States has the largest incident population of Acute Myeloid Leukemia (AML).
  • Among the EU5 countries, Germany had the highest incident cases of Acute Myeloid Leukemia (AML), followed by France. On the other hand, Spain had the lowest incident cases with 1,955 cases in 2020.
Scope of the Report
  • The Acute Myeloid Leukemia (AML) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Acute Myeloid Leukemia (AML) Epidemiology Report and Model provide an overview of Acute Myeloid Leukemia (AML) 's risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into Acute Myeloid Leukemia (AML) 's a historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute Myeloid Leukemia (AML).
  • The report provides the segmentation of the Acute Myeloid Leukemia (AML) epidemiology by the incidence of AML in 7MM.
  • The report provides the Acute Myeloid Leukemia (AML) epidemiology segmentation by Gender-specific cases of AML in 7MM.
  • The report provides the Acute Myeloid Leukemia (AML) epidemiology segmentation by Age-specific Cases of AML in 7MM.
  • The report provides the Acute Myeloid Leukemia (AML) epidemiology segmentation by Genetic Mutations in AML in 7MM.
Report Highlights
  • 10-year Forecast of Acute Myeloid Leukemia (AML) epidemiology
  • 7MM Coverage
  • Incidence of AML
  • Gender-specific cases of AML
  • Age-specific Cases of AML
  • Genetic Mutations in AML
KOL Views

The publisher interviews KOLs, and SMEs' opinions through primary research to fill the data gaps and validate the secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM for the patient population about Acute Myeloid Leukemia (AML)?
  • What are the key findings of the Acute Myeloid Leukemia (AML) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?
  • What would be the total number of Acute Myeloid Leukemia (AML) patients across the 7MM during the forecast period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2018-2030)?
  • What are the disease risk, burden, and unmet needs of Acute Myeloid Leukemia (AML)?
  • What are the currently available treatments for Acute Myeloid Leukemia (AML)?
Reasons to Buy

The Acute Myeloid Leukemia (AML) epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Acute Myeloid Leukemia (AML) market.
  • Quantify patient populations in the global Acute Myeloid Leukemia (AML) market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acute Myeloid Leukemia (AML) therapeutics in each of the markets covered.
  • Understand the magnitude of the Acute Myeloid Leukemia (AML) population by its incidence.
  • Understand the magnitude of the Acute Myeloid Leukemia (AML) population by its Gender-specific cases.
  • Understand the magnitude of the Acute Myeloid Leukemia (AML) population by its Age-specific cases.
  • Understand the magnitude of the Insomnia population by its Genetic Mutations.
  • The Acute Myeloid Leukemia (AML) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Acute Myeloid Leukemia (AML) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

According to a study by Medeiros et al. (2019), acute myeloid leukemia (AML) is the most common acute leukemia in adults. In the United States (US), the estimated prevalence of AML was 48,615 in 2011. It has been estimated that 19,520 new cases of AML will be diagnosed in 2018, and 10,670 deaths due to AML will be recorded. The incidence of AML increases with age, from 1.0 per 100,000 in patients aged 15-19 years to 28.5 per 100,000 in those aged 80-84 years; one-third of new cases are diagnosed in patients older than 75 years.

In the front-line setting, 60% of patients received high-intensity therapy, most commonly cytarabine plus anthracycline; the most common low-intensity treatments were hypomethylating agents. Primary drivers for selecting high-intensity versus low-intensity treatment were age, performance status, and comorbidities; 67%, 64%, and 61% of physicians stated they would prescribe high-intensity treatment to patients aged ≥60 years. Most patients in this analysis of real-world survey data received well-established, front-line induction therapies. Treatment intensity was determined by age, comorbidities, and performance status, as recommended by guidelines.
Note: Product cover images may vary from those shown
1 Key Insights

2 Report Introduction

3 Acute Myeloid Leukemia (AML) Market Overview at a Glance
3.1 Market Share (%) Distribution of Acute Myeloid Leukemia in 2018
3.2 Market Share (%) Distribution of Acute Myeloid Leukemia in 2030

4 Executive Summary of Acute Myeloid Leukemia (AML)

5 Disease Background and Overview
5.1 Introduction
5.2 Classification
5.3 Symptoms
5.4 Causes
5.5 Risk Factors
5.6 Pathophysiology
5.7 Gene mutations Associated With AML
5.8 Diagnosis
5.8.1 Diagnostic Algorithm
5.8.2 Diagnostic Guidelines
5.9 Prognosis Factors
5.1 Treatment
5.11 Treatment Guideline
5.11.1 AML in Adult Patients: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.11.2 NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Population of Acute Myeloid Leukemia
6.3 Epidemiology of Acute Myeloid Leukemia
6.4 The United States
6.4.1 Incidence of AML in the United States
6.4.2 Gender-specific cases in the United States
6.4.3 Age-specific cases in the United States
6.4.4 Genetic Mutations in AML in the United States
6.5 EU5
6.5.1 Germany
6.5.1.1 Incidence of AML in Germany
6.5.1.2 Gender-specific cases in Germany
6.5.1.3 Age-specific cases in Germany
6.5.1.4 Genetic Mutations in AML in Germany
6.5.2 France
6.5.2.1 Incidence of AML in France
6.5.2.2 Gender-specific cases in France
6.5.2.3 Age-specific cases in France
6.5.2.4 Genetic Mutations in AML in France
6.5.3 Italy
6.5.3.1 Incidence of AML in Italy
6.5.3.2 Gender-specific cases in Italy
6.5.3.3 Age-specific cases in Italy
6.5.3.4 Genetic Mutations in AML in Italy
6.5.4 Spain
6.5.4.1 Incidence of AML in Spain
6.5.4.2 Gender-specific cases in Spain
6.5.4.3 Age-specific cases in Spain
6.5.4.4 Genetic Mutations in AML in Spain
6.5.5 United Kingdom
6.5.5.1 Incidence of AML in the United Kingdom
6.5.5.2 Gender-specific cases in the United Kingdom
6.5.5.3 Age-specific cases in the United Kingdom
6.5.5.4 Genetic Mutations in AML in the United Kingdom
6.6 Japan
6.6.1 Incidence of AML in Japan
6.6.2 Gender-specific cases of AML in Japan
6.6.3 Age-specific cases of AML in Japan
6.6.4 Genetic Mutations in AML in Japan

7 KOL Views

8 Appendix
8.1 Bibliography
8.2 Report Methodology

9 Publisher Capabilities

10 Disclaimer

11 About the Publisher

List of Tables
Table 1: Summary of Acute Myeloid Leukemia, Market, Epidemiology, and Key Events (2018-2030)
Table 2: FAB Classification of AML
Table 3: WHO Classification of AML and Related Neoplasms
Table 4: Frequency and Clinical Significance of Recurrent Gene Mutations in Adults With AML
Table 5: Tests/procedures for a patient with AML
Table 6: Updated AML Risk Classification From the NCCN and ELN
Table 7: Total Incident Population of Acute Myeloid Leukemia in 7MM (2018-2030)
Table 8: Incidence of AML in the United States (2018-2030)
Table 9: Gender-specific cases of AML in the United States (2018-2030)
Table 10: Age-specific Cases of AML in the United States (2018-2030)
Table 11: Genetic Mutations in AML in the United States (2018-2030)
Table 12: Incidence of AML in Germany (2018-2030)
Table 13: Gender-specific cases of AML in Germany (2018-2030)
Table 14: Age-specific cases of AML in Germany (2018-2030)
Table 15: Genetic Mutations in AML in Germany (2018-2030)
Table 16: Incidence of AML in France (2018-2030)
Table 17: Gender-specific cases of AML in France (2018-2030)
Table 18: Age-specific cases of AML in France (2018-2030)
Table 19: Genetic Mutations in AML in France (2018-2030)
Table 20: Incidence of AML in Italy (2018-2030)
Table 21: Gender-specific cases of AML in Italy (2018-2030)
Table 22: Age-specific cases of AML in Italy (2018-2030)
Table 23: Genetic Mutations in AML in Italy (2018-2030)
Table 24: Incidence of AML in Spain (2018-2030)
Table 25: Gender-specific cases of AML in Spain (2018-2030)
Table 26: Age-specific cases of AML in Spain (2018-2030)
Table 27: Genetic Mutations in AML in Spain (2018-2030)
Table 28: Incidence of AML in the United Kingdom (2018-2030)
Table 29: Gender-specific cases of AML in the United Kingdom (2018-2030)
Table 30: Age-specific cases of AML in the United Kingdom (2018-2030)
Table 31: Genetic Mutations in AML in the United Kingdom (2018-2030)
Table 32: Incidence of AML in Japan (2018-2030)
Table 33: Gender-specific cases of AML in Japan (2018-2030)
Table 34: Age-specific cases of AML in Japan (2018-2030)
Table 35: Genetic Mutations in AML in Japan (2018-2030)

List of Figures
Figure 1: Development of Blood Cells.
Figure 2: Causes of CRS
Figure 3: Eight Functional Categories of Genes that are Commonly Mutated in AML.
Figure 4: Eight Functional Categories of Genes That are Commonly Mutated in AML.
Figure 5: Diagnostic Algorithm of AML.
Figure 6: Acute Leukemia Diagnostic Journey
Figure 7: Treatment Algorithm for First-Line Treatment in Newly Diagnosed AML Patients Eligible for Standard Induction and Consolidation Treatment
Figure 8: Treatment Algorithm for First-Line Treatment in Newly Diagnosed AML Patients not Eligible for Standard Induction and Consolidation Treatment
Figure 9: Treatment Algorithm for Second-Line Treatment in Relapsed/Refractory AML Patients
Figure 10: Treatment Induction (Physiologic Age < 60 Years)
Figure 11: AML Physiologic Age < 60 Years After Standard Dose Cytarabine Induction/Reinduction
Figure 12: AML Physiologic Age < 60 Years After High Dose Cytarabine Induction
Figure 13: Post Remission/Maintenance Therapy (Physiologic Age < 60 Years)
Figure 14: Treatment Induction (Physiologic Age ≥60 Years)
Figure 15: Treatment Induction (Physiologic Age ≥60 Years)
Figure 16: Standard Dose Cytarabine Induction (Physiologic Age ≥60 Years)
Figure 17: Post remission/Maintenance Therapy (Physiologic Age ≥60 Years)
Figure 18: Post-induction Therapy (Physiologic Age ≥60 Years)
Figure 19: AML Surveillance and Therapy for Relapse/Refractory (After Completion of Consolidation)
Figure 20: Total Incident Population of Acute Myeloid Leukemia in 7MM (2018-2030)
Figure 21: Incidence of AML in the United States (2018-2030)
Figure 22: Gender-specific cases of AML in the United States (2018-2030)
Figure 23: Age-specific Cases of AML in the United States (2018-2030)
Figure 24: Genetic Mutations in AML in the United States (2018-2030)
Figure 25: Incidence of AML in Germany (2018-2030)
Figure 26: Gender-specific cases of AML in Germany (2018-2030)
Figure 27: Age-specific cases of AML in Germany (2018-2030)
Figure 28: Genetic Mutations in AML in Germany (2018-2030)
Figure 29: Incidence of AML in France (2018-2030)
Figure 30: Gender-specific cases of AML in France (2018-2030)
Figure 31: Age-specific cases of AML in France (2018-2030)
Figure 32: Genetic Mutations in AML in France (2018-2030)
Figure 33: Incidence of AML in Italy (2018-2030)
Figure 34: Gender-specific cases of AML in Italy (2018-2030)
Figure 35: Age-specific cases of AML in Italy (2018-2030)
Figure 36: Genetic Mutations in AML in Italy (2018-2030)
Figure 37: Incidence of AML in Spain (2018-2030)
Figure 38: Gender-specific cases of AML in Spain (2018-2030)
Figure 39: Age-specific cases of AML in Spain (2018-2030)
Figure 40: Genetic Mutations in AML in Spain (2018-2030)
Figure 41: Incidence of AML in the United Kingdom (2018-2030)
Figure 42: Gender-specific cases of AML in the United Kingdom (2018-2030)
Figure 43: Age-specific cases of AML in the United Kingdom in 000s (2018-2030)
Figure 44: Genetic Mutations in AML in the United Kingdom (2018-2030)
Figure 45: Incidence of AML in Japan (2018-2030)
Figure 46: Gender-specific cases of AML in Japan in 000s (2018-2030)
Figure 47: Age-specific cases of AML in Japan (2018-2030)
Figure 48: Genetic Mutations in AML in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll